Growth hormone (GH) had direct effects on the glomerular podocyte. Increased levels of GH 25 are implicated in the pathogenesis of renal abnormalities in acromegaly and in diabetic 26 nephropathy in Type 1 diabetes mellitus. We investigated the role of Transforming growth 27 factor-β1 (TGF-β1) in GH's effects on the glomerular podocyte. Exposure of podocytes to GH 28 resulted in elevated expression of TGF-β1 and was concurrent with increased phosphorylation 29 of SMAD2/3 and nuclear accumulation of SMAD4. Conditioned media from podocytes exposed 30 to GH also triggered SMAD signaling. Podocytes treated with GH showed increased 31 permeability to albumin. Mice injected with GH demonstrated increased kidney size, glomerular 32 hypertrophy, and proteinuria. The renal manifestations in GH injected mice were associated with 33 increased TGF-β1 expression and activation of TGF-β1 signaling pathways. Concurrent 34 administration of TGF-β receptor antagonist (SB431542) with GH abrogated these renal effects 35 of GH administration. These results reveal the role of TGF-β1 in GH's actions on the glomerular 36 podocyte and provide a novel mechanistic basis for GH-induced glomerular dysfunction in 37 clinical conditions such as diabetes and acromegaly. 38 39 40 41 42 43
44

Introduction: 45
Diabetic nephropathy (DN) is characterized by an array of structural and functional aberrations 46 in the nephron. Structural changes include podocyte hypertrophy, glomerular sclerosis, and 47 thickening of the glomerular basement membrane (GBM). The functional manifestations include 48 a transient increase in glomerular filtration rate (GFR) and proteinuria ranging from 49 microalbuminuria to overt proteinuria. The magnitude of proteinuria reflects the extent of 50 damage to the glomerular filtration barrier (GFB), which consists of endothelial cells, basement 51 membrane and podocytes [1] . Podocytes are the specialized cells that offer epithelial coverage 52
to renal capillaries and serves as a final barrier to curb the loss of protein into the urine. Injury to 53 the podocytes including hypertrophy, foot process effacement, and epithelial-mesenchymal-54 transition (EMT) that eventually culminates into reduced podocyte count [2] . However, the 55 molecular signals that initiate these podocyte abnormalities remain incompletely understood. 56
Elevated growth hormone (GH) levels in poorly controlled type 1 diabetes mellitus (DM) is 57 implicated as a causative factor in the development of renal aberrations and proteinuria in DM 58 [2] [3] [4] . GH transgenic animals developed significant renal hypertrophy and glomerulosclerosis [5] . 59
Although certain biological effects of GH are mediated by insulin-like growth factor 1 (IGF-1), the 60 glomerular hypertrophy and significant renal manifestations are evidenced in GH transgenics 61 with IGF-1 null background [6] , suggesting that IGF-1 is not necessary for these effects of GH 62 on the glomerulus. In GH transgenic animals, podocytes undergo hypertrophy while mesangial 63 and endothelial cells undergo proliferation [6] . GH administration enhanced the effects of 64 streptozotocin (STZ)-induced diabetes on renal hypertrophy in rats [5] . Conversely, mice with 65 mutant GHR were protected from STZ-induced diabetic renal complications [7] . Similarly, in 66 animal models, somatostatin analogs (lanreotide and octreotide) that decrease GH secretion 67 offered substantial protection against DN [8] . Long-term treatment of acromegaly patients with 68 somatostatin analogues prevented GH-induced renal alterations [9] . This evidence argues for a 69 strong association between elevated GH levels and renal aberrations. Our earlier studies 70 identified that podocyte as a direct target for GH action and our subsequent studies 71 demonstrated that GH regulates expression of Smad interacting protein (SIP1) and transforming 72 growth factor β interacting protein (TGFBIP, also known as Bigh3) in podocytes [10] [11] [12] . 73
Transforming growth factor-β (TGF-β) is a master regulator of ECM turnover that is secreted 74 from most cell types in the body. Three TGF-β isoforms have been identified among which 75 isoform 1 (TGF-β1) has been associated with the pathophysiology of DN. Earlier studies 76 implicated TGF-β1 as a central molecule responsible for the excess deposition of ECM proteins 77 in diabetes [13] . Both mRNA and protein levels of TGF-β1 are significantly elevated in DN 78 patients [14, 15] . Studies from experimental diabetic animals further substantiated the role of 79 TGF-β1 in the pathogenesis of DN [16] . Neutralizing TGF-β1 with anti-TGF-β1 antibodies 80 reversed the established type II diabetic renal injury [17] . In the present study, we provide 81 evidence to substantiate the hypothesis that GH's effect on the glomerular podocyte is 82 transduced via the TGF-β/SMAD pathway. Our findings suggest a novel mechanism for GH's 83 actions on the glomerular podocyte 84 85
Materials and methods: 86
Materials: TGF-β1 antibody (#MA5-16949) and Lipofectamine (#11668019) were purchased 87 from Invitrogen. SMAD pathway antibodies were purchased from Novus Biologics (#NBP2-88 54771, NBP1-77836, AF3797, NBP2-67372). All secondary antibodies used for western blotting 89 in this study were from Jackson Laboratories (#111-035-144, 115-035-062) and fluorescent-90 tagged secondary antibodies from Vector Labs (#DI-1094, CY-2500). Human GH was 91 Genotropin (Pfizer) and recombinant TGF-β1 (#240-B-002) and ELISA kit for TGF-β1 92 (#DB100B) were procured from R&D systems. TGF-βR1 inhibitor (SB431542) was purchased 93 from Tocris Bioscience (#1614-10MG). Signal SMAD4 reporter plasmid encodes GFP gene 94 under minimal CMV promoter and tandem repeats of SMAD4 transcriptional response elements 95 (SA Biosciences). 96
Animal experiments and animal care: Swiss-albino mice were purchased from the National 97
Center for Laboratory Animal Sciences (NCLAS, NIN, Hyderabad). All experimental group 98 animals were maintained under 12hr day and night cycles throughout the experimental 99 procedure. After acclimatization animals are grouped into three groups: control, GH, GH+SB. 100
On day fifth of acclimatization, the GH group received intraperitoneal injections of GH (2mg/kg 101 body weight/day) and the GH+SB group received intraperitoneal injections of SB431542 102 (1mg/kg body weight/day) 1h prior to the GH treatment. All animals were sacrificed on day 14 th 103 post GH treatment, perfused with PBS and internal body fixation achieved by 4% PFA 104 (paraformaldehyde). The kidneys were collected and one kidney was used for histological 105 analysis and the other kidney was used for molecular signaling studies. Institutional Animal 106
Ethics Committee of University of Hyderabad approved the animal protocols. 107
Cell culture and treatments: Immortalized human podocytes were gifted by Prof. Moin Saleem 108 (University of Bristol, UK) cultured in 10% serum containing media prepared in RPMI 1640 with 109 1% antibiotic-antimycotic at 33ºC under 5% CO 2 . After cells reached 70% confluence, the cells 110 were transferred to 37ºC and maintained for 6-8 days for differentiation. Differentiated 111 podocytes were used for all treatments. Cells were serum starved in glucose-free RPMI media 112 for 24hr before being treated by human GH. All treatments were performed in serum and 113 glucose-free media. Before treating cells with GH or TGF-β1, cells were treated with SB431542 114 for 24h in serum and glucose-free medium. 115
Preparation of conditioned media: Differentiated podocytes were treated with or without GH 116 (500ng/ml) for 30 min. Subsequently these podocytes are thoroughly washed with RPMI1640 117 media to remove trace of GH and then cultured in fresh serum free RPMI1640 media, which 118 was collected 30 min later (Conditioned media). The conditioned media from GH-treated (CM-119 GH) and untreated (Con-CM) podocytes were centrifuged 6000xg for 5 min to remove cell 120 debris and resulting supernatant was further purified with 0.2 μ m membrane filters. Fresh batch 121 of differentiated podocytes were treated with Con-CM or GH-CM for 30 min to assess activation 122 of SMAD signaling or treated for 12 h for assessing morphological parameters. 123
SDS-PAGE & Western Blotting:
Unless otherwise mentioned, 10% SDS-PAGE gels were 124 used in this study. Cell lysates were prepared in RIPA lysis buffer and protein estimation was 125 done using Bradford standard method. Equal amounts of protein were loaded and gels were run 126 at 100 volts for 2hrs or until the dye was released. Western blotting was performed using 127 standard methods at 200mA for 1hr at 4 o C and PVDF membrane was used for all western 128 transfers. Blots were incubated with the respective primary antibody for overnight at 4 o C before 129 being incubated with respective secondary antibody for 1hr at room temperature. Blots were 130 developed using the ECL substrate employing Bio-Rad Versa Doc 5000 MFP and results were 131 analyzed in Image Lab and band intensities were quantified in Image J software developed by 132
NIH, Bethesda. 133
Immunohistochemistry: Paraffin-embedded tissues were processed into 6µm sections using a 134
Leica systems microtome. Sections were deparaffinized in xylene and rehydrated with ethanol 135 from 100% to 50%. Peroxidase blocking and permeabilization were performed in 30% H 2 O 2 for 136 25 min at room temperature. Antigen retrieval was done in Tris-EDTA-Tween buffer in the micro 137 oven (three cycles of five minutes with intervals of two minutes). Blocking was performed in 5% 138 BSA in PBS for 1hr at room temperature. Sections were incubated with primary antibody for two 139 hours followed by two washes with PBS and incubated with secondary antibody either with 140 fluorescent tagged or HRP (horseradish peroxidase) conjugate. Sections were developed using 141 DAB stain and counterstained with hematoxylin. All washes are done with PBS. Sections were 142 dehydrated and mounted with DPX mounting media. 143 Immunofluorescence: Immunofluorescence was performed according to a previous protocol 144
[12]. Briefly, cells were fixed with 4% PFA for 10 min on a glass coverslip and permeabilized 145 with 0.5% Triton X-100 for 15min at room temperature. Blocking was performed with 5% BSA in 146 PBS for 1hr and primary antibody was used at a 1:100 dilution. Cells were mounted with prolong 147 gold antifade with DAPI (Molecular Probes, #P36941). All washes are done with PBS. Imaging 148 was done in a Leica Microsystems trinocular or Zeiss confocal microscopy. 149 SMAD4-GFP Reporter Assay: SMAD4-GFP reporter assay was performed in HEK293T cells 150 according to the earlier published protocols with minor modifications [18] . In a 96 well plate, 151 6X10 3 cells/well were seeded prior to the day of transfection. Cells were transfected either with 152 SMAD4-GFP, positive control and negative control vectors in triplicates. After transfection cells 153
were left untreated in complete medium for 16h, followed by serum starvation for 12h. The cells 154
were then treated with TGFβ, GH CM or GH in serum-free medium. After 16h of treatment, 155 images were taken in Olympus 5000 fluorescence microscope and the fluorescence emission 156 spectrum from 510-520nm recorded by exciting at 488nm. Fluorescence values were plotted 157 after normalizing with mock test control values. 158
Transient transfection: All transient transfections were performed according to the 159 manufacturer protocol. 95% confluent HEK293T cells were transfected using lipofectamine 160 2000, Invitrogen. After 6hr of transection, cells were briefly washed with PBS and incubated in 161 10% serum containing media for 24hr followed by which all treatments were performed in 162 serum-free medium. 163 ELISA: Cells were serum starved in glucose-free RMPI 1640 medium for 24h under standard 164 culture conditions. Cells were treated with GH 250 and 500ng concentrations in the starvation 165 medium (not supplement with glucose) for 30min. Briefly, dead cells were removed from the cell 166 supernatants by centrifugation at 16000g for 10min at 4 o C and the supernatants were passed 167 through 0.2µm membrane filters. The resultant supernatants were directly subjected to the TGF-168 β 1 activation procedures as the manufacturer's protocol. Activated samples were assayed by 169 indirect sandwich Elisa kit (R&D systems # DB100B). 170 Paracellular albumin influx assay: Albumin influx assay was performed in podocytes as per 171 published methods [11]. 1.2X10 5 cells per well were seeded on to the top chamber of a 6-well 172 insert. The wells of the six-well plate were filled with 6ml of RPMI complete medium and 173 incubated under permissive conditions for 24h. Then cells were shifted to 37 o C and incubated 174 for 6-8 days for differentiation into mature podocytes before being serum starved for 24h and 175 the indicated treatments applied to the cells. After 48hr of treatment, cells were washed with 176 PBS supplemented with 1mM MgCl2 and 1mM CaCl2 to preserve cadherin junctions. Then, six-177 well plates were filled with 6ml of 40mg/ml BSA containing serum-free RPMI medium and the 178 top chamber filled only with 0.7ml of RPMI. After incubation, a small aliquot of a medium from 179 the top chamber was collected to measure BSA influx from bottom to top chamber and 180 concentration assessed by the BCA protein assay method. role of TGF-β1 in increasing podocyte permeability, we investigated the direct action of GH on 190 the TGF-β/SMAD pathway in human podocytes. We observed that GH (100-500 ng/ml) induces 191 TGF-β1 protein levels in human podocytes as analyzed by immunoblotting ( Fig 1A&B) . Since 192 TGF-β1 is a secretory molecule, we next estimated TGF-β1 concentration in conditioned 193 medium from GH treated podocytes. GH increased TGF-β1 concentration in both a dose (250 194 and 500 ng/ml) and time (0-60 min) dependent manner ( Fig 1C&D) . Furthermore, GH also 195 increased phosphorylation of SMAD2&3 in podocytes ( Fig 1E&F) . These results indicate that 196 GH induces expression of TGF-β1 and activation of TGF-β1 down-stream signaling in 197 podocytes. 198 199 GH induced TGF-β in podocytes acts in both autocrine and paracrine manner: TGF-β1 is 200 known to act in a both autocrine and paracrine manner. To elucidate the paracrine action of GH 201 induced TGF-β1, we treated podocytes with GH and collected conditioned media. Conditioned 202 media from GH-treated podocytes induced phosphorylation of SMAD2&3 in podocytes naïve to 203 GH (Fig 2A) . This suggests the possibility of GH-dependent secretion of TGF-β1 into the 204 conditioned media, which then elicited activation of SMAD2&3. TGF-β dependent regulation of 205 its target genes requires the interaction of SMAD4 with SMAD2&3 and the localization of the 206 SMAD2/3/4 complex to the nucleus. We observed increased accumulation of SMAD4 in the 207 nucleus following treatment with GH or conditioned media from GH-treated podocytes ( Fig 2B) . 208
We next performed TGF-β neutralization studies with podocytes transfected with a GFP 209 expression plasmid under the control of SMAD binding element. Both, GH and conditioned 210 media from GH treated podocytes induced GFP expression in this model ( Fig 2C) . However, 211 conditioned media from GH treated podocytes that were pre-incubated with anti-TGF-β1 212 antibody failed to induce GFP expression ( Fig 2C&D) . Furthermore, to verify that observed 213 effects of GH on activation of SMADs is mediated via GH-dependent secretion of TGF-β1 in 214 podocytes; we employed the TGF-βR1 inhibitor, SB431542 (hereafter named as SB). SB is a 215 small molecule that targets the TGF-β signaling pathway by competing for ATP binding domains 216 in the ALK5 (TGF-βR1) receptor [19] . SB treatment significantly reduced the TGF-β1 levels in 217 GH treated podocytes as measured by ELISA ( Fig 3A) and immunoblotting ( Fig 3B) . In addition, 218
we observed reduced phosphorylation of SMAD2&3 ( Fig 3C) and decreased nuclear levels of 219 SMAD4 ( Fig 3D) in podocytes treated with GH and SB. We next sought to study the functional 220 consequence of GH-dependent expression of TGF-β1 and down-stream activation of SMAD 221 signaling in podocytes using a paracellular albumin influx assay. Podocytes treated with GH 222 showed increased permeability to albumin across a podocyte monolayer ( Fig 3E) . Interestingly, 223 treatment with SB abrogated the observed effect of GH on podocyte permeability ( Fig 3E) . 224
Together, these data from either direct treatment with GH or from conditioned media from GH-225 treated podocytes demonstrate that TGF-β1 induced by GH acts in a both autocrine and 226 paracrine manner to activate SMAD signaling, which results in increased podocyte permeability. 227
228
GH alters podocyte morphology and regulates expression of ECM components in 229
podocytes: GH treated podocytes show increased cell size compared with podocytes naïve to 230 GH ( Fig 4A) . Similar to GH, TGF-β1 also induced an increase in podocyte cell size ( Fig 4A) . 231
Changes in the structural organization of the actin cytoskeleton usually accompany changes in 232 cell size. Profiling of F-actin polymerization in podocytes by Phalloidin staining revealed that 233 both TGF-β1 and GH increased F-actin polymerization in podocytes ( Fig 4B&C) . TGF-βR1 234 inhibitor (SB) attenuated GH induced increase in podocyte cell size ( Fig 4B&C) . Cell 235 morphology is also influenced by its interactions with ECM proteins and TGF-β1 is known to 236 play a critical role in ECM turnover. Next, we found increased expression of extracellular matrix 237 molecules in podocytes exposed to GH or TGF-β1 compared with cells naïve to these 238 molecules ( Fig 4D&E) . Increased expression of ECM proteins in podocytes correlates with 239 increased thickening of GBM observed in mice injected with GH ( Fig 4D&E Vs. Fig 6A&B) . 240
Activation of TGF-β/SMAD pathway in GH injected mice: To delineate the in vivo effect of 241
GH on TGF-β in the podocyte we administered GH to mice for two weeks. Compared with 242 control mice, GH injected mice had higher kidney (mg) to body weight (g) ratio (7.2 Vs. 8.46) 243 and increased glomerular size ( Fig 5A&B) . Histological analysis of kidney from GH injected mice 244 revealed mild to moderate renal fibrosis, mesangial expansion, and synechiae formation 245 between bowman's space and glomerular tufts ( Fig 5C) . There was also a significant decrease 246 in GFR in GH injected animals ( Fig 5D) . Analysis of podocyte architecture by transmission 247 electron microscopy revealed disruption of podocyte foot-processes and thickening of GBM (Fig  248   6A&B ). Urine from GH administered mice has higher albumin to creatinine ratio (UCAR, Fig 6C) 249 and more abundance of high molecular weight proteins ( Fig 6D) compared with control mice. 250
These results demonstrate that GH induces glomerular hypertrophy, alterations in podocyte 251 morphology, and impairment of renal function as evidenced by increased UCAR and decreased 252
GFR. 253
We conducted further analysis to understand the mechanism for the glomerular hypertrophy and 254 proteinuria in mice administered with GH. TGF-β1 levels were elevated in platelet poor plasma 255 preparations from GH injected mice ( Fig 7A) . Furthermore, glomerular lysates from GH injected 256 mice revealed an increased abundance of TGF-β1 protein ( Fig 7B&C) . Immunohistochemistry 257 analysis demonstrated increased expression of TGF-β1 in both glomerulus and renal tubule (Fig  258   7D ). Increased phosphorylation of SMAD2&3 was also observed in glomerular lysates from 259 mice administered with GH ( Fig 7E) . These results suggest that TGF-β1 mediates effects of GH 260 on the glomerular podocyte. 261 262 TGF-βR1 inhibitor attenuates GH induced renal anomalies: In order to ascertain that the 263 observed GH-dependent glomerular injury is specifically due to TGF-β1, we employed the TGF-264 β R1 inhibitor (SB) in our further studies. SB administration ameliorated alterations in kidney 265 (mg) to body weight (g) ratio in GH injected mice (7.9 Vs. 8.4) Administration of SB to mice prior 266 to the GH injection prevented the increase in TGF-β1 levels induced by GH injection (Fig 8A) . 267 SB treatment also alleviated the GH-induced glomerular hypertrophy and increases in 268 glomerular tuft area ( Fig 8B&C) and resulted in decreased activation of SMAD2&3 ( Fig 8D) . 269 Furthermore, SB treatment improved proteinuria in the GH-administered animals ( Fig 8E) . 270
These results support the hypothesis that TGF-β1 mediates effects of GH on the podocyte and 271 that inhibition of TGF-βR1 could prevent certain GH mediated adverse effects on the podocyte 272 and the glomerulus and the podocyte. 273 274
Discussion: 275
The current investigation reveals a novel mechanism for GH action on glomerular podocytes 276 and in the pathogenesis of diabetic nephropathy. The major findings of this study are that GH 277 induces TGF-β1 and the canonical TGF-β1/SMAD signaling pathway in glomerular podocytes. [13, 20] . Despite knowing the fact that TGF-β/SMAD pathway activation is 296 crucial in most of the kidney diseases, the stimuli that activate the TGF-β/SMAD pathway in the 297 podocyte remain unclear. Previous studies proposed that high glucose and angiotensin II 298 induces TGF-β1 expression in mesangial cells, however, in the podocytes, angiotensin II does 299 alter TGF-β expression. Although, elevated GH levels and overactivity of GH/GHR axis is 300 implicated in renal manifestations and CKD [2, 4] the temporal association between GH and 301 TGF-β is unclear. It is noteworthy that GH-induced mild glomerulosclerosis and interstitial 302 fibrosis in diabetic Sprague-Dawley rats is associated with an elevation in TGF-β1 levels [5] and 303 suppressing JAK2, an immediate downstream target of GH reduced TGF-β mRNA expression 304
[21]. In the present study, our results establish that GH stimulates expression of TGF-β1 in 305 podocytes and to best of our knowledge this is the first study to demonstrate GH induces TGF-306 β 1 expression. TGF-β1 is secreted from cells as a biologically inactive large latent complex 307 (LLC) [22] . LLC is composed of a family of latent TGF-β binding proteins (LTBP) that binds 308 covalently to TGF-β and facilitate efficient secretion and targeting TGF-β to the ECM. In our 309 earlier study, we reported that GH regulates expression of TGFBIp (TGF-beta interacting 310 protein, also known as BigH3), which is a member of the LTBP complex [10] . Hence, GH 311 increases TGF-β1 mediated renal effects by both increasing TGF-β1 and by regulating the 312 bioavailability of TGF-β1. 313 314 TGF-β family proteins are secreted proteins and elicit pleiotropic actions on target cells. Our 315 study suggests GH-dependent secretion of TGF-β1 elicits its action in a both autocrine and 316 paracrine manner. TGF-β1 binds and activate heteromeric complex (type I and II) of 317 transmembrane receptors. Upon binding with the ligand, type II receptor, which is a 318 constitutively active kinase phosphorylates the type I receptor. Activated type I receptor kinases 319 phosphorylate two serine residues in the "SSXS motif" of receptor-regulated SMADs (R-SMADs; 320 SMAD2&3). Phosphorylation enables the formation of heteromeric complexes between 321 SMAD2&3 and one common-SMAD, SMAD4, and translocation of the entire complex to the 322 nucleus [23] . We demonstrated GH-dependent activation of R-SMADs and localization of 323 SMAD4 in the podocyte nucleus. Nuclear translocation of SMAD4 is dependent on 324 phosphorylation of SMAD2&3 that form complex with SMAD4. Both direct exposure of 325 podocytes to GH and GH-conditioned media induced GFP expression from a transfected 326 plasmid containing GFP controlled by a putative SMAD4 binding element. The former actions 327 support autocrine action and later indicate paracrine action of TGF-β1. Furthermore, pre-328 treatment of GH-conditioned media with TGF-β1 neutralizing antibodies abolished the potential 329 of GH-conditioned media to activate SMAD4. It is noteworthy that podocytes exposed to GH-330 conditioned media that are prior exposed to TGF-βR1 inhibitor (SB) reduced the 331 phosphorylation of SMAD2&3. SMAD4 nuclear translocation also was prevented by treatment 332 with SB. These observations are congruent with the diminished levels of TGF-β1 in the 333 podocytes exposed to GH and SB. Our study also demonstrates that perturbing the TGF-334 β R1/SMAD pathway by SB prevented GH-mediated renal manifestations in mice suggesting the 335 autoregulation of TGF-β1. Our observation is supported by an earlier study where administration 336 of neutralizing TGF-β antibodies decreased the total production of TGF-β [22] . GH induces the 337 expression of ZEB2 (also known as Smad Interacting protein, SIP1) [11] . ZEB2 binds tightly to 338 activated RSMADs (SMAD2&3) and regulate Smad-mediated transcription even when ZEB 339 binding sites are absent from a target gene [24] . Together the data suggest GH regulates TGF-340 β R1/SMAD signaling at multiple levels. 341
Our study indicates that TGF-β1 elicits reorganization of the actin cytoskeleton in 342 podocytes. Podocytes are terminally differentiated cells and offer epithelial coverage to the 343 glomerular basement membrane. Neighboring foot-processes of podocytes are tethered by a 344 modified tight-junction known as slit-diaphragm (SD) that forms the major filtration-barrier at the 345 blood-urine interface. Podocyte foot-processes composed of the actin cytoskeleton. Therefore 346 actin cytoskeleton plays a vital role in normal biology of the podocyte and reorganization of the 347 actin cytoskeleton is expected to cause podocyte dysfunction, which results in 348 glomerulosclerosis and progressive kidney failure [25] . TGF-β1 induced reorganization of the 349 actin cytoskeleton and abnormal functioning of SD suggests a mechanistic link between 350 increased permeability to albumin across podocyte monolayer. Concomitantly, mice injected 351 with GH showed elevated TGF-β1 levels, effacement of podocyte foot-processes and 352 proteinuria. The validation of our hypothesis and the decisive role of TGF-β1 in transducing 353 GH's action on podocyte dysfunction will be investigated in future studies in the presence and 354 absence of TGF-β1 receptors. 355
The results of the current study demonstrate that GH's role in the pathogenesis of 356 nephropathy is at least in part is mediated by TGF-β1. A proposed model for GH and TGF-β1 357 axis is glomerular podocytes is depicted in Fig 9. However, further studies are required to 358 delineate the contribution of specific STATs in GH mediated TGF-β1 production. Based on our 359 observations, we propose that GH induces TGF-β1 expression and it could be implicated as a 360 causative factor in the development of renal hypertrophy, ECM accumulation, podocytopathy, 361 and proteinuria during GH-induced kidney diseases. In summary, the present report establishes 362 that GH induces TGF-β1 expression in podocytes and that some of the actions of GH on the 363 podocytes are mediated through TGF-β1 in a both autocrine and paracrine manner. Our data 364 provide a mechanistic link between GH and podocyte dysfunction in diseases like type I 365 diabetes mellitus and acromegaly. 
